Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910141254203321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development / / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development / / edited by Donglu Zhang, Sekhar Surapaneni |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910816078003321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analysis of aggregates and particles in protein pharmaceuticals [[electronic resource] /] / edited by Hanns-Christian Mahler, Wim Jiskoot
| Analysis of aggregates and particles in protein pharmaceuticals [[electronic resource] /] / edited by Hanns-Christian Mahler, Wim Jiskoot |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, Inc., 2012 |
| Descrizione fisica | 1 online resource (474 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
MahlerHanns-Christian
JiskootWim |
| Soggetto topico |
Pharmaceutical chemistry
Protein drugs - Analysis |
| ISBN |
1-283-40104-5
9786613401045 1-118-15056-2 1-118-15057-0 1-118-15054-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The critical need for robust assays for quantitation and characterization of aggregates of therapeutic proteins -- Separation based analytical methods for measuring protein aggregation -- Laser light scattering-based techniques used for the characterization of protein therapeutics -- Online detection methods and emerging techniques for soluble aggregates in protein pharmaceuticals -- Analytical methods to measure sub-visible particulates -- Detection of visible particles in parenteral products -- Characterization of aggregates and particles using emerging techniques -- Ultraviolet absorption spectroscopy -- Fluorescence spectroscopy to characterize protein aggregates and particles -- Infrared spectroscopy to characterize protein aggregates -- Raman microscopy for characterization of particles -- Microscopic methods for particle characterization in protein pharmaceuticals -- Comparison of methods for soluble aggregate detection and size characterization -- Protein purification and its relation to protein aggregation and particles -- Formulation development and its relation to protein aggregation and particles. |
| Record Nr. | UNINA-9910141229603321 |
| Hoboken, N.J., : John Wiley & Sons, Inc., 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analysis of aggregates and particles in protein pharmaceuticals / / edited by Hanns-Christian Mahler, Wim Jiskoot
| Analysis of aggregates and particles in protein pharmaceuticals / / edited by Hanns-Christian Mahler, Wim Jiskoot |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, Inc., 2012 |
| Descrizione fisica | 1 online resource (474 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
MahlerHanns-Christian
JiskootWim |
| Soggetto topico |
Pharmaceutical chemistry
Protein drugs - Analysis |
| ISBN |
1-283-40104-5
9786613401045 1-118-15056-2 1-118-15057-0 1-118-15054-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The critical need for robust assays for quantitation and characterization of aggregates of therapeutic proteins -- Separation based analytical methods for measuring protein aggregation -- Laser light scattering-based techniques used for the characterization of protein therapeutics -- Online detection methods and emerging techniques for soluble aggregates in protein pharmaceuticals -- Analytical methods to measure sub-visible particulates -- Detection of visible particles in parenteral products -- Characterization of aggregates and particles using emerging techniques -- Ultraviolet absorption spectroscopy -- Fluorescence spectroscopy to characterize protein aggregates and particles -- Infrared spectroscopy to characterize protein aggregates -- Raman microscopy for characterization of particles -- Microscopic methods for particle characterization in protein pharmaceuticals -- Comparison of methods for soluble aggregate detection and size characterization -- Protein purification and its relation to protein aggregation and particles -- Formulation development and its relation to protein aggregation and particles. |
| Record Nr. | UNINA-9910824569603321 |
| Hoboken, N.J., : John Wiley & Sons, Inc., 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applications of transition metal catalysis in drug discovery and development [[electronic resource] ] : an industrial perspective / / edited by Matthew L. Crawley, Barry M. Trost
| Applications of transition metal catalysis in drug discovery and development [[electronic resource] ] : an industrial perspective / / edited by Matthew L. Crawley, Barry M. Trost |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (376 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
CrawleyMatthew L
TrostBarry M |
| Soggetto topico |
Drug development
Transition metal catalysts |
| ISBN |
1-280-59238-9
9786613622211 1-118-30983-9 1-118-30987-1 1-118-30986-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Transition metal catalysis in the pharmaceutical industry / Carl A. Busacca ... [et al.] -- Selected applications of transition metal-catalyzed carbon-carbon cross-coupling reactions in the pharmaceutical industry / Hong C. Shen -- Selected applications of Pd and Cu-catalyzed carbon-heteroatom cross-coupling reactions in the pharmaceutical industry / Jingjun Yin -- Asymmetric cross-coupling reactions / William A. Szabo and Vince Yeh -- Metathesis / Oliver Thiel -- Transition metal-catalyzed synthesis of five and six membered heterocycles / Cheol K. Chung and Matthew L. Crawley -- Oxidative catalysis / Lamont Terrell -- Industrial asymmetric hydrogenation / Hans-Ulrich Blaser. |
| Record Nr. | UNINA-9910141266003321 |
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applications of transition metal catalysis in drug discovery and development : an industrial perspective / / edited by Matthew L. Crawley, Barry M. Trost
| Applications of transition metal catalysis in drug discovery and development : an industrial perspective / / edited by Matthew L. Crawley, Barry M. Trost |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (376 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
CrawleyMatthew L
TrostBarry M |
| Soggetto topico |
Drug development
Transition metal catalysts |
| ISBN |
1-280-59238-9
9786613622211 1-118-30983-9 1-118-30987-1 1-118-30986-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Transition metal catalysis in the pharmaceutical industry / Carl A. Busacca ... [et al.] -- Selected applications of transition metal-catalyzed carbon-carbon cross-coupling reactions in the pharmaceutical industry / Hong C. Shen -- Selected applications of Pd and Cu-catalyzed carbon-heteroatom cross-coupling reactions in the pharmaceutical industry / Jingjun Yin -- Asymmetric cross-coupling reactions / William A. Szabo and Vince Yeh -- Metathesis / Oliver Thiel -- Transition metal-catalyzed synthesis of five and six membered heterocycles / Cheol K. Chung and Matthew L. Crawley -- Oxidative catalysis / Lamont Terrell -- Industrial asymmetric hydrogenation / Hans-Ulrich Blaser. |
| Record Nr. | UNINA-9910808689303321 |
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applying genomic and proteomic microarray technology in drug discovery / / Robert S. Matson
| Applying genomic and proteomic microarray technology in drug discovery / / Robert S. Matson |
| Autore | Matson Robert S. |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Boca Raton : , : Taylor & Francis, , 2013 |
| Descrizione fisica | 1 online resource (313 p.) |
| Disciplina | 615.1/9 |
| Soggetto topico |
High throughput screening (Drug development)
DNA microarrays Protein microarrays Pharmacogenomics Proteomics |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-429-10783-8
1-4398-5564-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Omics & microarrays revisited -- The commercial microarray -- Supports & surface chemistries -- The arraying process -- Gene expression microarray-based applications -- Protein microarray applications -- Multiplex assays. |
| Record Nr. | UNINA-9910462913103321 |
Matson Robert S.
|
||
| Boca Raton : , : Taylor & Francis, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applying genomic and proteomic microarray technology in drug discovery / / Robert S. Matson
| Applying genomic and proteomic microarray technology in drug discovery / / Robert S. Matson |
| Autore | Matson Robert S. |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Boca Raton : , : Taylor & Francis, , 2013 |
| Descrizione fisica | 1 online resource (313 p.) |
| Disciplina | 615.1/9 |
| Soggetto topico |
High throughput screening (Drug development)
DNA microarrays Protein microarrays Pharmacogenomics Proteomics |
| ISBN |
0-429-10783-8
1-4398-5564-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Omics & microarrays revisited -- The commercial microarray -- Supports & surface chemistries -- The arraying process -- Gene expression microarray-based applications -- Protein microarray applications -- Multiplex assays. |
| Record Nr. | UNINA-9910786247103321 |
|
Matson Robert S.
|
||
| Boca Raton : , : Taylor & Francis, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applying genomic and proteomic microarray technology in drug discovery / / Robert S. Matson
| Applying genomic and proteomic microarray technology in drug discovery / / Robert S. Matson |
| Autore | Matson Robert S. |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Boca Raton : , : Taylor & Francis, , 2013 |
| Descrizione fisica | 1 online resource (313 p.) |
| Disciplina | 615.1/9 |
| Soggetto topico |
High throughput screening (Drug development)
DNA microarrays Protein microarrays Pharmacogenomics Proteomics |
| ISBN |
0-429-10783-8
1-4398-5564-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Omics & microarrays revisited -- The commercial microarray -- Supports & surface chemistries -- The arraying process -- Gene expression microarray-based applications -- Protein microarray applications -- Multiplex assays. |
| Record Nr. | UNINA-9910800038603321 |
|
Matson Robert S.
|
||
| Boca Raton : , : Taylor & Francis, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Artificial Intelligence and Machine Learning in Drug Design and Development
| Artificial Intelligence and Machine Learning in Drug Design and Development |
| Autore | Khanna Abhirup |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2024 |
| Descrizione fisica | 1 online resource (670 pages) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
El BarachiMay
JainSapna KumarManoj NayyarAnand |
| Collana | Fintech in a Sustainable Digital Society Series |
| Soggetto topico | Drug development |
| ISBN |
1-394-23419-8
1-394-23418-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910877054203321 |
|
Khanna Abhirup
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
